Drug Profile

FZ 002 - Guangzhou Fermion Technology

Alternative Names: FZ-002 - Guangzhou Fermion Technology; FZ002-037

Latest Information Update: 15 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Guangzhou Fermion Technology
Class Non-opioid analgesics; Small molecules
Mechanism of Action Somatostatin receptor subtype 4 agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase I Pain

Most Recent Events

15 Oct 2025 Phase-I development is ongoing in Pain (In volunteers) in China (PO) (Guangzhou Fermion Technology pipeline; October 2025)
17 Jan 2025 FZ 002 licensed to Simcere Pharmaceutical Group in China, Hong Kong, Macau and Taiwan
17 Jan 2025 Guangzhou Fermion Technology plans a phase II trial for Diabetic nephropathies

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com